Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure

Executive Summary

Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.

You may also be interested in...



CHMP Negative On PharmaMar's Aplidin In Multiple Myeloma

Clouds are gathering over Spanish firm PharmaMar as the EU's CHMP rejects its multiple myeloma therapy Aplidin. Its reasons are not yet forthcoming.

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.

PharmaMar Aims For A Second Marketed Product With EU Aplidin Filing

Spanish company PharmaMar has filed for approval of its anticancer Aplidin in the EU, which if successful would be its second product to reach the market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel